These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Designer drugs. Patients may be using synthetic cannabinoids more than you think. Lisi DM JEMS; 2014 Sep; 39(9):56-9. PubMed ID: 25322519 [TBL] [Abstract][Full Text] [Related]
4. [Prehospital emergency. Abuse of psychotropics: medicines and drugs]. Yersin B; Feiner AS; Livio F Rev Med Suisse; 2013 Nov; 9(406):2120-9. PubMed ID: 24383287 [No Abstract] [Full Text] [Related]
5. Mixed consumption of cannabis and "Spice". Dziadosz M; Klintschar M; Teske J Forensic Sci Int; 2014 Feb; 235():e1-2. PubMed ID: 24389330 [No Abstract] [Full Text] [Related]
6. [Designer drugs--diagnostic, psychological and low aspects of problem]. Morawska-Siudak J; Szkolnicka B; Gomółka E; Krawczyk-Pasławska E Przegl Lek; 2010; 67(8):598-601. PubMed ID: 21387785 [TBL] [Abstract][Full Text] [Related]
7. Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents. Meyer MR; Maurer HH Anal Bioanal Chem; 2012 Jan; 402(1):195-208. PubMed ID: 21866399 [TBL] [Abstract][Full Text] [Related]
8. Effect of law enforcement action on K2 abuse trends. Hassen GW; Roy A; Amilineni T; Chirurgi R; Almond G; Kalantari H Am J Emerg Med; 2018 Jun; 36(6):1119-1120. PubMed ID: 29122374 [No Abstract] [Full Text] [Related]
9. New Drugs of Abuse and Withdrawal Syndromes. Andrabi S; Greene S; Moukaddam N; Li B Emerg Med Clin North Am; 2015 Nov; 33(4):779-95. PubMed ID: 26493523 [TBL] [Abstract][Full Text] [Related]
10. Analytical toxicology of emerging drugs of abuse--an update. Meyer MR; Peters FT Ther Drug Monit; 2012 Dec; 34(6):615-21. PubMed ID: 23131695 [TBL] [Abstract][Full Text] [Related]
11. The emerging threat of synthetic cannabinoids. Phillips J; Lim F; Hsu R Nurs Manage; 2017 Mar; 48(3):22-30. PubMed ID: 28234762 [No Abstract] [Full Text] [Related]
13. Query and test for synthetic cannabinoids in drug treatment and research. Ninnemann A; MacPherson L Int J Drug Policy; 2015 May; 26(5):531-2. PubMed ID: 25540864 [No Abstract] [Full Text] [Related]
14. Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. Spinelli E; Barnes AJ; Young S; Castaneto MS; Martin TM; Klette KL; Huestis MA Drug Test Anal; 2015 Jun; 7(6):467-74. PubMed ID: 25167963 [TBL] [Abstract][Full Text] [Related]
15. Screening of synthetic cannabinoids in preserved oral fluid by UPLC-MS/MS. Oiestad EL; Johansen U; Christophersen AS; Karinen R Bioanalysis; 2013 Sep; 5(18):2257-68. PubMed ID: 24053241 [TBL] [Abstract][Full Text] [Related]
16. Adding Spice to the Porridge: The development of a synthetic cannabinoid market in an English prison. Ralphs R; Williams L; Askew R; Norton A Int J Drug Policy; 2017 Feb; 40():57-69. PubMed ID: 27955961 [TBL] [Abstract][Full Text] [Related]
17. Toxicology and management of novel psychoactive drugs. Kersten BP; McLaughlin ME J Pharm Pract; 2015 Feb; 28(1):50-65. PubMed ID: 25261428 [TBL] [Abstract][Full Text] [Related]
18. Geographic distribution of synthetic cannabinoid exposures reported to Texas poison centers. Forrester MB; Haywood T Am J Drug Alcohol Abuse; 2012 Nov; 38(6):603-8. PubMed ID: 22571605 [TBL] [Abstract][Full Text] [Related]
19. [The illegal synthetic cannabinoid drug market in Israel - evolution and new challenges]. Shapira B; Poperno A; Berkovitz R Harefuah; 2016 Sep; 155(9):526-530. PubMed ID: 28530077 [TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation following synthetic cannabinoid abuse. Efe TH; Felekoglu MA; Çimen T; Doğan M Turk Kardiyol Dern Ars; 2017 Jun; 45(4):362-364. PubMed ID: 28595208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]